通过半结构化访谈评估血小板生成素受体激动剂药物对儿童免疫性血小板减少症患者结局与生活质量的影响
这项单中心整合性混合方法研究纳入23例符合条件的儿童免疫性血小板减少症(ITP)患者,其中20例参与半结构化访谈。病历回顾显示11/20例患者达到血小板计数≥50×10^9/L持续六周以上且无需挽救治疗。访谈中19/20例认为血小板生成素受体激动剂(TPO-RA)「有效」,11/20例报告情绪获益,11/20例报告活动/运动参与增加。研究提示TPO-RA可改善儿童ITP患者的生活质量。
要点
- 病历回顾中11/20例儿童ITP患者达到血小板计数≥50×10^9/L持续六周以上且无需挽救治疗。
- 访谈中19/20例儿童和/或照护者认为TPO-RA「有效」。
- 访谈中17/20例对药物费用、10/20例对给药方式、10/20例对潜在副作用表示担忧。
核心结论
- 研究提示TPO-RA用于儿童ITP可改善生活质量。
研究设计与样本
- 单中心整合性混合方法研究,纳入23例符合条件的儿童ITP患者,其中20例参与半结构化访谈,并独立进行回顾性病历回顾收集ITP相关数据与TPO-RA数据。
主要发现
- 病历回顾中11/20例患者达到血小板计数≥50×10^9/L持续六周以上且无需挽救治疗。
- 访谈中19/20例儿童和/或家长认为TPO-RA「有效」。
- 访谈中11/20例报告情绪获益,11/20例报告活动/运动参与增加。
- 访谈中17/20例对TPO-RA药物费用表示担忧,10/20例对给药方式表示担忧,10/20例对潜在副作用表示担忧。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the last decade, treatment of immune thrombocytopenia (ITP) in children has advanced to include thrombopoietin receptor agonist (TPO-RA) medications. Concurrently, there has been an increased emphasis on patient-reported outcomes-especially quality of life-to guide treatment. Assessing the impact of TPO-RAs on quality of life in paediatric ITP is therefore a priority. In this single-centre integrative mixed-methods study, a cohort of children with ITP prescribed a TPO-RA was identified. These children and/or their caregivers were invited to participate in semi-structured interviews focussed on quality-of-life measures. Independently, a retrospective chart review collected ITP-related data (platelet count, bleeding events) and TPO-RA data (dosing, side effects). Among the 23 eligible patients, 20 were represented in interviews. On chart review, 11/20 patients responded to TPO-RA by meeting platelet count criteria of ≥50 × 109 /L for six or more weeks in the absence of rescue therapy. In interviews with these children and/or their parents, 19/20 expressed the TPO-RA had 'worked', with 11/20 reporting benefit to mood and 11/20 reporting increased participation in activities/sports. Concerns were raised in interviews about TPO-RA medication cost (17/20), medication administration (10/20) and potential side effects (10/20). In conclusion, this study suggests that TPO-RA use in children with ITP improves quality of life.
引用
- Livingston J, Alrajhi Z, Jackson M, et al. Evaluating the impact of thrombopoietin receptor agonist medications on patient outcomes and quality of life in paediatric immune thrombocytopenia through semi-structured interviews. Br J Haematol. 2022. PMID: 36345812. doi:10.1111/bjh.18545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。